Zim Laboratories Limited has informed the Exchange about Investor Presentation
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zim Laboratories reported FY25 Total Operating Income of ₹3,790 Mn, up 3.2% YoY, with export revenue rising 8.9% to ₹3,125 Mn (82% of revenue). EBITDA grew 6.4% to ₹495 Mn with margins improving to 13.1% from 12.7% in FY24. However, Profit After Tax declined to ₹122 Mn (from ₹172 Mn) due to higher finance costs (₹114 Mn vs ₹69 Mn) and depreciation (₹201 Mn vs ₹160 Mn). The company acknowledged underperformance versus its own guidance, citing political instability and currency issues in core markets. The innovative product basket (NIP + OTF) grew 68% YoY to ₹624 Mn, now contributing 19% of revenue. Q4 FY25 was stronger, with TOI up 12.9% QoQ to ₹1,087 Mn, EBITDA margin reaching 15%, and PAT up 22.1% QoQ to ₹49 Mn.
The presentation shows margin improvement and strong growth in high-value innovative products, which is positive for the long-term story. However, the miss against earlier guidance and the sharp PAT decline due to rising interest and depreciation costs from heavy capex (₹365 Mn) may concern short-term investors. Gearing remains elevated at 44%, though marginally improved.